AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL) Revenue
Annual & quarterly revenue history · segment & region breakdown
ABCL · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAbCellera Biologics Inc. trailing twelve-month (TTM) revenue is $0.08B, an increase of 160.56% year-over-year from $0.08B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.08B | +$0.05B | +160.56% |
| 2024-12-31 | $0.03B | -$0.01B | -24.17% |
| 2023-12-31 | $0.04B | -$0.45B | -92.17% |
| 2022-12-31 | $0.49B | +$0.11B | +29.38% |
| 2021-12-31 | $0.38B | +$0.14B | +60.92% |
| 2020-12-31 | $0.23B | +$0.22B | +1907.88% |
| 2019-12-31 | $0.01B | +$0.00B | +31.49% |
| 2018-12-31 | $0.01B | — | — |
Compare revenue vs peers
BiotechnologyCompare ABCL revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income AbCellera Biologics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
AbCellera Biologics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from AbCellera Biologics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ABCL revenue · 4 questionsABCL's trailing twelve-month (TTM) revenue is $0.08B. That is an increase of 160.56% year-over-year from $0.08B in FY2025.
▸ Source: FMP · AbCellera Biologics Inc. SEC filings · GAAP · AbCellera Biologics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026